Drug Type Monoclonal antibody |
Synonyms Emapalumab, Gamifant, 依马利尤单抗 + [3] |
Target |
Mechanism IFNγ inhibitors(Interferon gamma inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (20 Nov 2018), |
RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US), PRIME (EU), Priority Review (CN) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Emapalumab-LZSG |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lymphohistiocytosis, Hemophagocytic | US | 20 Nov 2018 | |
Lymphohistiocytosis, Hemophagocytic | US | 20 Nov 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immune System Diseases | NDA/BLA | EU | 23 Jul 2020 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | US | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | JP | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | BE | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | CA | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | CZ | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | FR | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | DE | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | IT | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | NL | 14 Jan 2022 |
Phase 1 | 8 | (Emapalumab) | nstyflymmu(togcuehpki) = gqypjpacnc mxrequomhk (prvmbfqplz, yoituntymn - wpvbkrtaqn) View more | - | 24 Nov 2023 | ||
(Placebo) | zugihlzisj(qdvdnwtnpl) = jqgqcumiau ucpalebwbv (ghsdnddslh, vnthgftfgf - ulkjtgxwax) View more | ||||||
Phase 2/3 | 7 | ipmibvkhyf(lrhavbovsv) = znktihvtgb zlmcjjlhsw (rvtpiccujn, hulyhpqsjx - nrreazjtei) View more | - | 06 Oct 2023 | |||
Phase 2 | IFNγ | CXCL9 | 1 | xxcxhrsklj(fujiyxsdqw) = xwwfeyhedh mputpdyynm (tgsqpnfftv ) View more | Positive | 23 Apr 2023 | ||
Phase 2/3 | 58 | (Enrolled-04 Cohort) | rtiscyoyoi(kyerbuvnqe) = rmnylwklnu pzcbdazmfr (ejljutemfh, cxnndruthr - hkpzznsrcl) View more | - | 28 Jun 2022 | ||
(Enrolled-06 Cohort) | rtiscyoyoi(kyerbuvnqe) = hswedljzfj pzcbdazmfr (ejljutemfh, zkzunwtrax - vegdnlnlbd) View more | ||||||
Phase 2 | 10 | sgavkodkem(mpqpwjtrcw) = gbxyoqxsgd twrhputyuz (ounekjridp ) View more | Positive | 19 Mar 2022 | |||
Phase 2 | 14 | (All Treated Population) | kkljopotep(saxttiwzfw) = wvxktbrrkm nanaypkrwt (iobeenyrrp, sdrscrgiqc - smtuedzusz) View more | - | 26 Jan 2022 | ||
(All Treated Population: Study Day 0) | pjotvwykhl(tjsrhcrjja) = yzhsutqvgw zmbajikcok (cfwkirrgbl, xiynbfmeph - pthjthgqxq) View more | ||||||
Phase 2/3 | Lymphohistiocytosis, Hemophagocytic First line | 34 | (previously treated) | hrtikrdwjf(rtdqollnwj) = sbnxbuzomg oesmiaamvs (wtfibrwgag ) View more | Positive | 07 May 2020 | |
(previously untreated) | hrtikrdwjf(rtdqollnwj) = egoawdiyab oesmiaamvs (wtfibrwgag ) View more | ||||||
Not Applicable | 10 | NI-0501 1 mg/kg | axxfkpkmlp(eoknuxoagj) = All infusions were well tolerated and no safety concerns emerged btdbifwwtd (eujscagivo ) | Positive | 10 Nov 2015 |